Pharmstandard Ventures

General contacts
Investor type

CVC / VC

Founded

2013

AUM

-

Location

Moscow, Moscow, Russia

Investment Ticket

$10-50 m

Investment Stage

Pre-seed Seed Series A Series B Late Stage (Series C+)

Region of investment

North America South America Europe Middle East Africa Asia Australia and others
Investor profile last updated: 22 August, 2026

Profile

Pharmstandard Ventures is a venture capital firm based in Russia, operating as the venture arm of Pharmstandard, JSC, a leading pharmaceutical company. Founded in 2013 originally as Inbio Ventures, the firm rebranded as Pharmstandard Ventures after a corporate restructuring in 2017. The team comprises professionals with extensive experience in the academic and biopharmaceutical sectors, as well as venture investments, focusing on breakthrough drug development projects globally.

The firm specializes in innovative drug discovery and development projects targeting unmet medical needs. Its investments focus on therapeutic areas such as oncology, inflammation, ophthalmology, autoimmune diseases, orphan genetic diseases, metabolic disorders, fibrotic diseases, and cell-based therapy. Pharmstandard Ventures partners with national market leaders like Pharmstandard and Generium for licensing and co-development opportunities in the Russian/CIS markets.

Notable portfolio companies of Pharmstandard Ventures include Jounce Therapeutics, which is focused on cancer treatment, Neon Therapeutics, specializing in immune system therapies for cancer, and Protagonist Therapeutics, which develops targeted oral peptide therapies for inflammatory bowel diseases. Other significant investments are Avelas Biosciences, a developer of platform technology for cell-penetrating peptides, and TearSolutions, Inc., in the realm of ophthalmological treatments.

Industry

MedTech Pharmaceuticals HealthTech Life Sciences Medical Devices Healthcare Services Biotechnology

Contacts

Name
Title
Email
Social Networks
avatar
Vadim Gorbunov Investment Manager
Investment Manager
-
LinkedIn
avatar
Elena Starikova Acting Head
Acting Head
-
LinkedIn
Upgrade to see contacts
avatar
g4V3mSisKo0wHcra g4V3mSisKo0wHcra
g4V3mSisKo0wHcra
[email protected]
linkedin twitter
avatar
g4V3mSisKo0wHcra g4V3mSisKo0wHcra
g4V3mSisKo0wHcra
[email protected]
linkedin twitter
avatar
g4V3mSisKo0wHcra g4V3mSisKo0wHcra
g4V3mSisKo0wHcra
[email protected]
linkedin twitter
Investment-team contacts for Pharmstandard Ventures — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Pharmstandard Ventures

Pharmstandard Ventures is a venture capital firm that also operates as a corporate VC (CVC). It backs companies at Pre-seed, Seed, Series A, Series B and Late Stage (Series C+), writing tickets of $10-50 m.
Pharmstandard Ventures is located in Moscow, Moscow, Russia.
Pharmstandard Ventures was founded in 2013.
Pharmstandard Ventures invests in companies and startups in MedTech, Pharmaceuticals, HealthTech, Life Sciences, Medical Devices, Healthcare Services, Biotechnology.
Pharmstandard Ventures invests in companies and startups in North America, South America, Europe, Middle East, Africa, Asia, Australia and others.
Pharmstandard Ventures invests in companies and startups at Pre-seed, Seed, Series A, Series B, Late Stage (Series C+).
Pharmstandard Ventures usually invests $10-50 m on average.
Pharmstandard Ventures can be reached through its website pharmstd-ventures.com. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Pharmstandard Ventures — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Pharmstandard Ventures directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 22 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.